Kim M. Olthoff, MD - Transplantation

Dr. Olthoff's current research involves both human translational studies and clinical research in the field of liver transplantation and liver cancer. Her work focuses on liver regeneration and early allograft dysfunction in the transplant setting, genomics and genetics of transplantation, as well as investigations in the development, treatment, and prevention of hepatocellular carcinoma.

These lines of investigation are funded by NIH grants, private industry, and the Biesecker Center for Pediatric Liver Disease. The Penn Transplant Institute research personnel have published in top-ranked journals such as Nature Medicine, Hepatology, American Journal of Transplantation, Liver Transplantation and Transplantation.

Human Translational Studies

  1. The Biorepository of the Transplant Institute at Penn (BioTIP). Dr. Olthoff is the PI for this large biorepository of blood, serum, and tissue samples from transplant recipieints and living donors. The repository serves as a valuable resource for numerous collaborations and ancillary studies.
  2. Liver Regeneration and Function in the Transplant Setting. Assessment of liver growth and function in donors and recipients following partial hepatectomy, living donor transplantation, and deceased donor transplantation using genomics, proteomics, and metabolomics.
  3. Use of cfDNA for detection of early HCC. Whole genome sequencing (WGS)-based technology for the detection of early hepatocellular carcinoma (HCC) in patients with and without HCC.

Clinical Research

  1. Clinical variables that impact liver regeneration after LD transplantation by volumetric imaging
  2. Variables impacting Early Allograft Dysfunction (EAD) and effect on post-transplant survival. Effect of ex vivo machine perfusion on incidence of EAD
  3. Outcomes of liver transplantation for HCC
    1. Impact of pretransplant locoregional therapy for HCC on post-transplant outcomes
    2. Transplantation for patients outside of Milan criteria
    3. Post-transplant adjuvant therapy and immunosuppression for patients with HCC (2 clinical trials ongoing)